Thanks Mh68All top 10 major pharma have an interest in the OA...

Thanks Mh68

All top 10 major pharma have an interest in the OA space to varying levels of current R&D investment and all are cashed-up with a constant need to refill their respective pipelines.

PAR is familiar with DeveInsight's research and there are other similar research providers of this OA market landscape overviews.

At a top level they see IA HA getting further traction given existing issues with NSAID, Opioids & Corticoids. However, I also note HA injections were previously taken off medicare due to studies that suggested it had limited duration.

Nevertheless their report also suggested:

Zilosul: Wannabe Blockbuster Therapy?

Webelieve that, given long-term efficacy and stable safety data, Zilosul will addsignificant value to the treatment of Knee Osteoarthritis by addressing certaincritical unmet needs. Furthermore, if the company receives a disease-modifyingosteoarthritis drug (DMOAD) designation, the drug will be eligible for apremium pricing, increasing the overall revenue of the product. However, as perour estimates, even if the drug does not receive DMOAD designation andconservative pricing, the drug is expected to achieve approximately USD850 million by 2032 in the 7MM.